All In MedTech

PMA device

GORE® VIABAHN® FORTEGRA Venous Stent

Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

2

Breakthrough-designated

Device trials

3

Naming "GORE VIABAHN FORTEGRA"

MAUDE reports

0

Brand "GORE VIABAHN FORTEGRA", since 2015

PubMed studies

0

Mentioning "GORE VIABAHN FORTEGRA"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing GORE® VIABAHN® FORTEGRA Venous Stent

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 2 of 2 decisions filed under this name.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "GORE VIABAHN FORTEGRA", any status and sponsor, newest update first.

Open in Trial Radar
  • W.L.Gore & AssociatesNot on our public-company list

    NCT07538609 · 150 participants (planned) · Start Aug 25, 2026 · Primary completion May 2029

    Device: GORE® VIABAHN® FORTEGRA Venous Stent · For: Venous Thromboses; Venous Disease; Venous Leg Ulcer and 5 more

    Sites: Darien, Connecticut; Washington D.C., District of Columbia; Dallas, Texas · 4 sites in all

  • W.L.Gore & AssociatesNot on our public-company list

    NCT05409976 · 136 participants · Start Oct 25, 2022 · Primary completion May 9, 2026

    Device: GORE® VIAFORT Vascular Stent · For: Venous Thromboses; Venous Disease; Venous Leg Ulcer and 7 more

    Sites: Stanford, California; Washington D.C., District of Columbia; Chicago, Illinois · 17 sites in all

  • W.L.Gore & AssociatesNot on our public-company list

    NCT05489588 · 165 participants (planned) · Start Mar 2, 2023 · Primary completion Aug 2027

    Device: GORE® VIAFORT Vascular Stent · For: Venous Thromboses; Venous Disease; Venous Leg Ulcer and 7 more

    Sites: Stanford, California; Darien, Connecticut; New Haven, Connecticut · 24 sites in all

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "GORE VIABAHN FORTEGRA", and for the whole product code for context.

This brand

0 reports: 0 malfunction, 0 injury, 0 death

Whole product code QTL

8 reports: 1 malfunction, 7 injury, 0 death

Newest reports for this brand

No MAUDE reports name this brand.

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recall in FDA's data is linked to these FDA numbers.

Published research

The most relevant PubMed records for "GORE VIABAHN FORTEGRA"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

No PubMed record mentions this device by name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.